Your browser doesn't support javascript.
loading
A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial.
McKetin, Rebecca; Degan, Tayla J; Saunders, Lucy; Nguyen, Long; Dore, Gregory; Shoptaw, Steven; Farrell, Michael; Degenhardt, Louisa; Kelly, Peter J; Turner, Alyna; Clare, Philip J; Dean, Olivia M; Arunogiri, Shalini; Colledge-Frisby, Samantha; Koeijers, Juanita; Goodman-Meza, David; Sinclair, Barbara; Reid, David; Hill, Harry; Hayllar, Jeremy; Christmass, Michael; Cordaro, Frank; Lundin, Robert; Liaw, Willy; Liu, Danica; Holyoak, Ellie; Wu, Brian Tid-Fung; Keygan, Joel; Kontogiannis, Ava; Palmer, Lily; Morrison, Caity; Wrobel, Anna; Hyland, Bec; Byrne, Marianne; Russell, Samantha; Zahra, Emma; Berk, Michael.
Affiliation
  • McKetin R; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. r.mcketin@unsw.edu.au.
  • Degan TJ; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
  • Saunders L; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
  • Nguyen L; Burnet Institute, Melbourne, Australia.
  • Dore G; Kirby Institute, University of New South Wales, Sydney, Australia.
  • Shoptaw S; Department of Family Medicine, David Geffen School of Medicine, Los Angeles, USA.
  • Farrell M; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
  • Degenhardt L; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
  • Kelly PJ; School of Psychology, Faculty of Arts, Social Sciences and Humanities, University of Wollongong, Wollongong, Australia.
  • Turner A; IMPACT, School of Medicine, Deakin University, Geelong, Australia.
  • Clare PJ; Prevention Research Collaboration, The University of Sydney, Sydney, Australia.
  • Dean OM; IMPACT, School of Medicine, Deakin University, Geelong, Australia.
  • Arunogiri S; Alfred Psychiatry Research Centre (MAPrc), Central Clinical School, Monash University, Melbourne, Australia.
  • Colledge-Frisby S; Burnet Institute, Melbourne, Australia.
  • Koeijers J; National Drug Research Institute, Curtin University, Perth, Australia.
  • Goodman-Meza D; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
  • Sinclair B; Center for HIV Identification, Prevention, and Treatment Services, Los Angeles, USA.
  • Reid D; Illawarra Drug and Alcohol Service, Illawarra Shoalhaven Local Health District, NSW Health, Wollongong, Australia.
  • Hill H; Illawarra Drug and Alcohol Service, Illawarra Shoalhaven Local Health District, NSW Health, Wollongong, Australia.
  • Hayllar J; Drug and Alcohol Services, Barwon Health, Geelong, Australia.
  • Christmass M; Biala City Community Health Centre, Metro North Health, Brisbane, Australia.
  • Cordaro F; Next Step Community Alcohol and Drug Service East Perth, East Perth, Australia.
  • Lundin R; Illawarra Drug and Alcohol Service, Illawarra Shoalhaven Local Health District, NSW Health, Wollongong, Australia.
  • Liaw W; Drug and Alcohol Services, Barwon Health, Geelong, Australia.
  • Liu D; Drug and Alcohol Services of South Australia, Adelaide, Australia.
  • Holyoak E; Drug and Alcohol Services of South Australia, Adelaide, Australia.
  • Wu BT; Alcohol, Tobacco & Other Drug Services, Townsville, Australia.
  • Keygan J; Alcohol, Tobacco & Other Drug Services, Townsville, Australia.
  • Kontogiannis A; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
  • Palmer L; School of Psychology, Faculty of Arts, Social Sciences and Humanities, University of Wollongong, Wollongong, Australia.
  • Morrison C; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
  • Wrobel A; IMPACT, School of Medicine, Deakin University, Geelong, Australia.
  • Hyland B; IMPACT, School of Medicine, Deakin University, Geelong, Australia.
  • Byrne M; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
  • Russell S; Kirby Institute, University of New South Wales, Sydney, Australia.
  • Zahra E; IMPACT, School of Medicine, Deakin University, Geelong, Australia.
  • Berk M; Grampians Health, Ballarat, Australia.
Trials ; 25(1): 408, 2024 Jun 22.
Article in En | MEDLINE | ID: mdl-38907288
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Randomized Controlled Trials as Topic / Clinical Trials, Phase III as Topic / Amphetamine-Related Disorders / Mirtazapine / Methamphetamine Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Oceania Language: En Journal: Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2024 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Randomized Controlled Trials as Topic / Clinical Trials, Phase III as Topic / Amphetamine-Related Disorders / Mirtazapine / Methamphetamine Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Oceania Language: En Journal: Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2024 Document type: Article Affiliation country: Country of publication: